View Future GrowthVitrolife 過去の業績過去 基準チェック /06Vitrolifeの収益は年間平均-49.2%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 15.2%割合で 増加しています。主要情報-49.15%収益成長率-49.64%EPS成長率Biotechs 業界の成長17.04%収益成長率15.19%株主資本利益率-62.07%ネット・マージン-147.17%次回の業績アップデート16 Jul 2026最近の業績更新お知らせ • Oct 25+ 3 more updatesVitrolife AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Vitrolife AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Nov 16Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025お知らせ • Oct 27Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026お知らせ • Jul 24+ 1 more updateVitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025Vitrolife AB (publ) announced that they will report Q3, 2025 results on Oct 29, 2025お知らせ • Feb 02+ 1 more updateVitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Vitrolife AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024お知らせ • Jan 24Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021.すべての更新を表示Recent updatesお知らせ • May 07+ 1 more updateVitrolife AB (publ) Approves Dividend, Payable on 12 May 2026Vitrolife AB (publ) at its Annual General Meeting held on May 5, 2026, resolved to distribute a dividend of SEK 1.10 per share. The record date for the dividend is 7 May 2026. Payment is expected to be made on 12 May 2026.お知らせ • Feb 03+ 2 more updatesVitrolife AB (publ), Annual General Meeting, May 05, 2026Vitrolife AB (publ), Annual General Meeting, May 05, 2026. Location: gothenburg Swedenお知らせ • Oct 25+ 3 more updatesVitrolife AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Vitrolife AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Apr 29Vitrolife AB (Publ) Approves Dividend for the Financial Year 2024Vitrolife AB (publ) at its AGM held on April 29, 2025, approved dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.お知らせ • Apr 10Vitrolife AB (publ) Announces CFO ChangesVitrolife AB (publ) announced that Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration. Helena Wennerström will remain as acting CFO until Pär takes office.お知らせ • Mar 31Vitrolife AB (Publ) Appoints Rickard Ericsson as Svp InnovationVitrolife AB (publ) announced that Rickard Ericsson, formerly SVP Consumables and SVP Sales & Marketing, has been appointed SVP Innovation, effective immediately. With over ten years at the company, Rickard brings a deep understanding of the reproductive health market. In this new role, he will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management, and Market Access. The Executive Management Team (EMT) now consists of: CEO: Bronwyn Brophy O'Connor Acting CFO: Helena Wennerström, COO: Ermanno Sironi, SVP Innovation: Rickard Ericsson, SVP Sales & Marketing: Olivia Natens, CHRO: Jessica Jonasson.お知らせ • Feb 21The Vitrolife Group Appoints Ermanno Sironi as Chief Operating OfficerThe Vitrolife Group appointed Ermanno Sironi as Chief Operating Officer effective immediately. The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as the IT organisation. The appointment supports continued execution of the corporate strategy to drive operational excellence, implementing a scalable operating model, optimising processes to realise synergies and leveraging digitalisation to increase productivity. Ermanno Sironi is a tenured MedTech executive with over 30 years' experience working in Operations, Finance and Business Development in global companies. Over the past year, he has served as a strategic advisor on operational excellence and business transformation to the Vitrolife Group's executive management team.お知らせ • Jan 31Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025. Location: gothenburg, Swedenお知らせ • Jan 30Vitrolife AB (Publ) Proposes DividendThe Board of Vitrolife AB (publ) proposed to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share.お知らせ • Dec 03Vitrolife AB (Publ) Announces Chief Financial Officer ChangesVitrolife AB (publ) announced that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Helena Wennerström will immediately assume the role of acting CFO and Patrik will be here to support her during a transition period. The recruitment of a permanent CFO is being initiated.お知らせ • Nov 16Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025お知らせ • Oct 27Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026お知らせ • Oct 04Vitrolife AB (Publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Patricia Hedelius, appointed by AMF Fonder & Pension; Jón Sigurdsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024.お知らせ • Jul 24+ 1 more updateVitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025Vitrolife AB (publ) announced that they will report Q3, 2025 results on Oct 29, 2025お知らせ • May 23Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.Vitrolife AB (publ) (OM:VITR) completed the acquisition of Stb Zorg B.V. on May 22, 2024. In 2023, Stb Zorg B.V. had revenues of €1.5 million.お知らせ • May 03Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.お知らせ • Apr 27Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023Vitrolife AB (publ) at the Annual General Meeting held on 25 April 2024, approved dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day.お知らせ • Feb 02+ 1 more updateVitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Vitrolife AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024お知らせ • Jan 24Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021.お知らせ • Oct 06Vitrolife AB (publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for the Annual General Meeting in 2024: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Caroline Sjösten, appointed by Swedbank Robur Fonder AB; and Jón Sigurdsson, Chairman of the Board.お知らせ • Aug 24Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice PresidentVitrolife AB (publ) announced that Maria Forss, has resigned from her position as SVP Consumables business area in the company as she will assume the role of CEO BICO Group AB. Maria has been employed within the company since 2012 and has been leading the Consumables business area since 2017.お知らせ • Aug 01Vitrolife AB Announces Board ChangesVitrolife AB (publ) announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB (publ) and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from August 1, 2023, when Bronwyn Brophy assumes the position as CEO. The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ). Vesa Koskinen has been a board member since 1 December 2021 and will step down as of today. After the announced changes, the Board consists of the Chairman of the Board Jón Sigurdsson and the board members Henrik Blomquist, Karen Lykke Sørensen, Lars Holmqvist and Pia Marions. Henrik Blomquist will replace Vesa Koskinen in the Audit Committee.お知らせ • Jul 14+ 4 more updatesVitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vitrolife AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024お知らせ • Feb 02+ 1 more updateVitrolife AB (publ) Proposes Dividend for 2022Vitrolife AB (publ) proposed a dividend of SEK 0.85 per share for 2022 compared to SEK 0.80 per share a year ago, corresponding to SEK 115 million (SEK 108 million a year ago).お知らせ • Feb 01Vitrolife AB (publ) Announces Executive ChangesVitrolife AB (publ) appointed Bronwyn Brophy as new CEO. Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors of the company find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value. Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region. Bronwyn Brophy will join the company at the latest on 1 August 2023. As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023.お知らせ • Oct 27+ 2 more updatesVitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023Vitrolife AB (publ) announced that they will report first half, 2023 results on Jul 14, 2023収支内訳Vitrolife の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:VTRL.Y 収益、費用、利益 ( )SEK Millions日付収益収益G+A経費研究開発費31 Mar 263,405-5,0111,33112431 Dec 253,440-5,0121,31811830 Sep 253,5074401,28411030 Jun 253,5414551,26211331 Mar 253,6104981,24311031 Dec 243,6095131,23211730 Sep 243,555-3,8051,18111730 Jun 243,535-3,7991,15011831 Mar 243,499-3,8361,11812631 Dec 233,512-3,8511,11712730 Sep 233,4624021,09212230 Jun 233,4123881,07612431 Mar 233,3364121,04813331 Dec 223,2343941,00214330 Sep 222,89335396115730 Jun 222,50134981115131 Mar 222,05430565613331 Dec 211,68134150311430 Sep 211,54941535310330 Jun 211,4643993339431 Mar 211,2913253089131 Dec 201,2462873119230 Sep 201,2732763249730 Jun 201,33129434210231 Mar 201,50237736510531 Dec 191,48038335110030 Sep 191,3913713428830 Jun 191,2973393188031 Mar 191,1993242937431 Dec 181,1513102847230 Sep 181,1022942787030 Jun 181,0642842767031 Mar 181,0662762766931 Dec 171,0462642706930 Sep 171,0262552667130 Jun 179912342627031 Mar 179132112546831 Dec 168561902506230 Sep 168041882355530 Jun 167711962315531 Mar 167471862235331 Dec 157221832205630 Sep 156601542135630 Jun 1560913719548質の高い収益: VTRL.Yは現在利益が出ていません。利益率の向上: VTRL.Yは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: VTRL.Yは利益が出ておらず、過去 5 年間で損失は年間49.2%の割合で増加しています。成長の加速: VTRL.Yの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: VTRL.Yは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: VTRL.Yは現在利益が出ていないため、自己資本利益率 ( -62.07% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 11:48終値2026/05/19 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vitrolife AB (publ) 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関null nullABG Sundal CollierKallum TitchmarshBofA Global ResearchKallum TitchmarshBofA Global Research9 その他のアナリストを表示
お知らせ • Oct 25+ 3 more updatesVitrolife AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Vitrolife AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Nov 16Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025
お知らせ • Oct 27Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026
お知らせ • Jul 24+ 1 more updateVitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025Vitrolife AB (publ) announced that they will report Q3, 2025 results on Oct 29, 2025
お知らせ • Feb 02+ 1 more updateVitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Vitrolife AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024
お知らせ • Jan 24Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021.
お知らせ • May 07+ 1 more updateVitrolife AB (publ) Approves Dividend, Payable on 12 May 2026Vitrolife AB (publ) at its Annual General Meeting held on May 5, 2026, resolved to distribute a dividend of SEK 1.10 per share. The record date for the dividend is 7 May 2026. Payment is expected to be made on 12 May 2026.
お知らせ • Feb 03+ 2 more updatesVitrolife AB (publ), Annual General Meeting, May 05, 2026Vitrolife AB (publ), Annual General Meeting, May 05, 2026. Location: gothenburg Sweden
お知らせ • Oct 25+ 3 more updatesVitrolife AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Vitrolife AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Apr 29Vitrolife AB (Publ) Approves Dividend for the Financial Year 2024Vitrolife AB (publ) at its AGM held on April 29, 2025, approved dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.
お知らせ • Apr 10Vitrolife AB (publ) Announces CFO ChangesVitrolife AB (publ) announced that Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration. Helena Wennerström will remain as acting CFO until Pär takes office.
お知らせ • Mar 31Vitrolife AB (Publ) Appoints Rickard Ericsson as Svp InnovationVitrolife AB (publ) announced that Rickard Ericsson, formerly SVP Consumables and SVP Sales & Marketing, has been appointed SVP Innovation, effective immediately. With over ten years at the company, Rickard brings a deep understanding of the reproductive health market. In this new role, he will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management, and Market Access. The Executive Management Team (EMT) now consists of: CEO: Bronwyn Brophy O'Connor Acting CFO: Helena Wennerström, COO: Ermanno Sironi, SVP Innovation: Rickard Ericsson, SVP Sales & Marketing: Olivia Natens, CHRO: Jessica Jonasson.
お知らせ • Feb 21The Vitrolife Group Appoints Ermanno Sironi as Chief Operating OfficerThe Vitrolife Group appointed Ermanno Sironi as Chief Operating Officer effective immediately. The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as the IT organisation. The appointment supports continued execution of the corporate strategy to drive operational excellence, implementing a scalable operating model, optimising processes to realise synergies and leveraging digitalisation to increase productivity. Ermanno Sironi is a tenured MedTech executive with over 30 years' experience working in Operations, Finance and Business Development in global companies. Over the past year, he has served as a strategic advisor on operational excellence and business transformation to the Vitrolife Group's executive management team.
お知らせ • Jan 31Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025. Location: gothenburg, Sweden
お知らせ • Jan 30Vitrolife AB (Publ) Proposes DividendThe Board of Vitrolife AB (publ) proposed to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share.
お知らせ • Dec 03Vitrolife AB (Publ) Announces Chief Financial Officer ChangesVitrolife AB (publ) announced that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Helena Wennerström will immediately assume the role of acting CFO and Patrik will be here to support her during a transition period. The recruitment of a permanent CFO is being initiated.
お知らせ • Nov 16Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025
お知らせ • Oct 27Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026
お知らせ • Oct 04Vitrolife AB (Publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Patricia Hedelius, appointed by AMF Fonder & Pension; Jón Sigurdsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024.
お知らせ • Jul 24+ 1 more updateVitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025Vitrolife AB (publ) announced that they will report Q3, 2025 results on Oct 29, 2025
お知らせ • May 23Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.Vitrolife AB (publ) (OM:VITR) completed the acquisition of Stb Zorg B.V. on May 22, 2024. In 2023, Stb Zorg B.V. had revenues of €1.5 million.
お知らせ • May 03Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.
お知らせ • Apr 27Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023Vitrolife AB (publ) at the Annual General Meeting held on 25 April 2024, approved dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day.
お知らせ • Feb 02+ 1 more updateVitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Vitrolife AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024
お知らせ • Jan 24Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021.
お知らせ • Oct 06Vitrolife AB (publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for the Annual General Meeting in 2024: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Caroline Sjösten, appointed by Swedbank Robur Fonder AB; and Jón Sigurdsson, Chairman of the Board.
お知らせ • Aug 24Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice PresidentVitrolife AB (publ) announced that Maria Forss, has resigned from her position as SVP Consumables business area in the company as she will assume the role of CEO BICO Group AB. Maria has been employed within the company since 2012 and has been leading the Consumables business area since 2017.
お知らせ • Aug 01Vitrolife AB Announces Board ChangesVitrolife AB (publ) announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB (publ) and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from August 1, 2023, when Bronwyn Brophy assumes the position as CEO. The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ). Vesa Koskinen has been a board member since 1 December 2021 and will step down as of today. After the announced changes, the Board consists of the Chairman of the Board Jón Sigurdsson and the board members Henrik Blomquist, Karen Lykke Sørensen, Lars Holmqvist and Pia Marions. Henrik Blomquist will replace Vesa Koskinen in the Audit Committee.
お知らせ • Jul 14+ 4 more updatesVitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vitrolife AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024
お知らせ • Feb 02+ 1 more updateVitrolife AB (publ) Proposes Dividend for 2022Vitrolife AB (publ) proposed a dividend of SEK 0.85 per share for 2022 compared to SEK 0.80 per share a year ago, corresponding to SEK 115 million (SEK 108 million a year ago).
お知らせ • Feb 01Vitrolife AB (publ) Announces Executive ChangesVitrolife AB (publ) appointed Bronwyn Brophy as new CEO. Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors of the company find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value. Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region. Bronwyn Brophy will join the company at the latest on 1 August 2023. As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023.
お知らせ • Oct 27+ 2 more updatesVitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023Vitrolife AB (publ) announced that they will report first half, 2023 results on Jul 14, 2023